Physician profile
Basil Omar Burney
NPI 1043414485
$899,899.73
in general payments reported to CMS, 2019-2025
60 companies · $163K in 2025
The $163K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131K · 2020: $75K · 2021: $96K · 2022: $172K · 2023: $152K · 2024: $110K · 2025: $163K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $393K · Travel and Lodging: $16K · Food and Beverage: $16K · Education: $94.28 · Consulting Fee: $41.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $392,839.19 |
| Travel and Lodging | $16,281.14 |
| Food and Beverage | $16,076.66 |
| Education | $94.28 |
| Consulting Fee | $41.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $349,096.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $337,055.10 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132,942.54 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $21,302.05 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $21,118.98 | 2021-2025 | |
| Dexcom, INC. | $15,194.22 | 2019-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $11,467.29 | 2019-2025 | Tepezza, Evenity, Prolia |
| Corcept Therapeutics | $2,904.16 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals Lp | $909.67 | 2019-2023 | Farxiga |
| Abbott Laboratories | $837.40 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $761.43 | 2019-2025 | |
| Recordati_rare_diseases_inc. | $531.59 | 2023-2025 | Isturisa, Signifor Lar |
| Amarin Pharma, INC. | $456.06 | 2019-2023 | |
| Insulet Corporation | $452.05 | 2019-2025 | Omnipod |
| Abbvie INC. | $424.03 | 2020-2025 | Synthroid |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $392.60 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $376.52 | 2019-2025 | Afrezza |
| Antares Pharma, INC. | $296.20 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Ibsa Pharma INC. | $270.53 | 2019-2025 | Tirosint, Licart, Flector |
| Tandem Diabetes Care, INC. | $250.39 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $205.68 | 2022-2025 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $203.44 | 2022-2025 | Strensiq |
| Cequr Corporation | $170.34 | 2022-2025 | Cequr Simplicity |
| Beta Bionics, INC. | $165.63 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sequel Med Tech, LLC | $159.07 | 2025 | Twiist |
| Amneal Pharmaceuticals LLC | $153.29 | 2022-2025 | Unithroid |
| Acella Pharmaceuticals, LLC | $153.05 | 2022-2025 | NP Thyroid 60 |
| Horizon Therapeutics Plc | $128.09 | 2022-2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $127.71 | 2025 | Yorvipath |
| Echosens North America, INC. | $119.25 | 2025 | Fibroscan |
| Neurocrine Biosciences, INC. | $103.05 | 2024-2025 | |
| Vivus LLC | $102.05 | 2019-2024 | Qsymia |
| Nevro Corp. | $94.42 | 2023-2024 | Senza |
| Madrigal Pharmaceuticals | $79.59 | 2025 | Rezdiffra |
| Medtronic Minimed, INC. | $77.12 | 2019-2020 | |
| Astellas Pharma US INC | $71.89 | 2024-2025 | Veozah |
| Eisai INC. | $65.33 | 2019 | |
| Pfizer INC. | $62.76 | 2019-2022 | |
| Radius Health, INC. | $59.51 | 2023-2025 | Tymlos |
| Rhythm Pharmaceuticals, INC. | $54.43 | 2022 | |
| Kyowa Kirin, INC. | $48.47 | 2024-2025 | Crysvita |
| Avvisto Therapeutics, LLC | $44.92 | 2024-2025 | Cycloset |
| Halozyme INC | $42.78 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $35.09 | 2023-2025 | Baqsimi |
| Shire North American Group INC | $33.02 | 2019 | |
| Merck Sharp & Dohme LLC | $28.58 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $28.11 | 2019 | |
| Chiesi USA, INC. | $24.72 | 2024 | Mycapssa |
| Alvogen INC | $21.23 | 2023 | Teriparatide |
| Glaxosmithkline, LLC. | $20.72 | 2025 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $20.38 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.31 | 2019 | |
| Lifescan, INC. | $20.03 | 2019 | |
| Ascensia Diabetes Care US INC. | $19.53 | 2025 | |
| Esperion Therapeutics, INC. | $19.31 | 2021 | |
| Intuity Medical INC | $18.28 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Ultragenyx Pharmaceutical INC. | $17.53 | 2022 | |
| Amryt Pharma Holdings Ltd | $17.10 | 2023 | Mycapssa |
| Currax Pharmaceuticals LLC | $15.94 | 2024 | Contrave |
| Senseonics, Incorporated | $9.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basil Burney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.